In a report issued on May 16, Jack Allen from Robert W. Baird maintained a Buy rating on Homology Medicines (FIXX – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.51, close to its 52-week low of $1.39. According to TipRanks.com, Allen has 0 stars on 0-5 stars ranking scale with an average return of -37.1% and a 11.1% success rate. Allen covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Taysha Gene Therapies, and Voyager Therapeutics. Currently, the analyst consensus on Homology Medicines is a Moderate Buy with an average price target of $10.64.
https://www.tipranks.com/news/blurbs/robert-w-baird-thinks-homology-medicines-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Homology Medicines Charts.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Homology Medicines Charts.